Michigan Patent of the Month – January 2024
Immunolight, LLC has pioneered a new method to trigger cell-to-cell communication within living subjects, opening new avenues in the realm of biotechnology and healthcare. This innovative technique, outlined in their recent patent, involves manipulating the cellular environment to induce biological changes in specific regions, ultimately leading to therapeutic outcomes.
The method begins by providing a first region of biological material coupled to the subject. This region is strategically chosen to initiate a change in the cellular environment. The change is not a random process; instead, it involves altering the rate of transport of reagents through cell membranes by manipulating the probability of tunneling. This is achieved by applying a photon flux to the reagents, increasing their energy.
The biological or chemical activity of cells in the first region then undergoes a transformation, leading to a biological change in a second region inside the subject. Notably, this method showcases adaptability in triggering cell-to-cell communication. It can be applied to regions formed of the subject’s own tissue or biological material implanted inside the subject. The inclusion of artificial materials capable of transmitting biophotons further broadens the scope, enhancing the precision and control over the process.
The patent delves into the possibility of quantum entangled regions, introducing a fascinating dimension to the technology. Additionally, the coupling mechanism involves interactions of DNA molecules along a pathway, introducing the concept of signaling DNA. This further refines the precision of inducing biological changes in specific regions.
The background of the invention elucidates the cellular structures involved, emphasizing the importance of the plasma membrane, cytoskeleton, and cellular communication. The patent positions the invention as a sophisticated tool capable of leveraging the inherent electrochemical nature of cells.
Immunolight was founded with the intention of creating new advancements in energy conversion technologies and applying these in the medicinal, commercial, and life science industries. Currently, Immunolight’s technology is focused on inducing immune responses against cancer by directing light within a tumor.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
